PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Nature. Author manuscript; available in PMC 2011 July 13.
Published in final edited form as:
PMCID: PMC3058308
NIHMSID: NIHMS249755

Structure of a nanobody-stabilized active state of the β2 adrenoceptor

Abstract

G protein coupled receptors (GPCRs) exhibit a spectrum of functional behaviors in response to natural and synthetic ligands. Recent crystal structures provide insights into inactive states of several GPCRs. Efforts to obtain an agonist-bound active-state GPCR structure have proven difficult due to the inherent instability of this state in the absence of a G protein. We generated a camelid antibody fragment (nanobody) to the human β2 adrenergic receptor (β2AR) that exhibits G protein-like behavior, and obtained an agonist-bound, active-state crystal structure of the receptor-nanobody complex. Comparison with the inactive β2AR structure reveals subtle changes in the binding pocket; however, these small changes are associated with an 11Å outward movement of the cytoplasmic end of transmembrane segment 6, and rearrangements of transmembrane segments 5 and 7 that are remarkably similar to those observed in opsin, an active form of rhodopsin. This structure provides insights into the process of agonist binding and activation.

GPCR Active States

GPCRs activated by diffusible ligands exhibit a spectrum of functional states 1. A GPCR may activate more than one G protein isoform or a G protein independent pathway such as arrestin. In the absence of a ligand, many GPCRs exhibit some basal, agonist independent activity towards one or more of these signaling pathways. Orthosteric ligands (compounds that occupy the native hormone binding pocket) are classified according to their efficacy, i.e., the effect that they have on receptor signaling through a specific pathway. Inverse agonists inhibit basal activity while agonists maximally activate the receptor. Partial agonists induce submaximal activity, even at saturating concentrations. Neutral antagonists have no effect on basal activity, but sterically block the activity of other ligands. Moreover, the efficacy profile of ligands for a given GPCR can differ for different down-stream signaling pathways. The presence of some activity in the unliganded receptor implies low energy barriers between functional states, such that thermal fluctuations significantly sample activating conformations, and ligands with distinct efficacy profiles act by stabilizing distinct subsets of conformations.

We know little about the structural basis for the functional versatility of GPCRs. Only rhodopsin has been crystallized in different conformational states 2,3,4,5. The first structures of rhodopsin covalently bound to 11-cis-retinal represent a completely inactive state with virtually no basal activity 5. Structures of opsin, the ligand free form of rhodopsin, obtained from crystals grown at pH 5.6 likely represent active conformations 2,3. The FTIR spectrum of opsin at acidic pH resembles that of metarhodopsin II, the light activated form of rhodopsin6. For rhodopsin, the light-induced transition from the inactive to the active state is very efficient. Rhodopsin is activated by photoisomerization of a covalent ligand, with efficient transfer of energy from the absorbed photon to the receptor. Crystal structures of low-pH opsin reveal that the protein conformation is the same in the presence or absence of a peptide from the alpha subunit of transducin (Gt), its cognate G protein, consistent with the notion that metarhodopsin II can adopt a fully active conformation in the absence of Gt.

The crystal structures of GPCRs activated by diffusible ligands, including the human β2AR 7,8,9,10, the avian β1AR 11, and the human adenosine A2A receptor12, represent inactive conformations bound by inverse agonists. Unlike the activation of rhodopsin by light, agonists are much less efficient at stabilizing the active state of the β2AR, making it difficult to capture this state in a crystal structure. Fluorescence lifetime studies show that even saturating concentrations of the full agonist isoproterenol do not stabilize a single active conformation 13. This may be due to the relatively low affinity and rapid rates of association and dissociation for β2AR agonists. Experiments using a β2AR labeled with a conformationally sensitive fluorescent probe show that stabilization of the active state requires both agonist and Gs, the stimulatory G protein for adenylyl cyclase14. Efforts to obtain an agonist-GPCR-G protein complex are of great importance; however, this is a particularly difficult endeavor due to the biochemical challenges in working with both GPCRs and G proteins, and the inherent instability of the complex in detergent solutions. As an alternate approach, we developed a binding protein that preferentially binds to and stabilizes an active conformation, acting as a surrogate for Gs.

Nanobody-stabilized β2AR active state

The active G protein coupled state of the β2AR (and many other family A GPCRs) exhibits characteristic functional properties. Agonists promote Gs binding to the β2AR and G protein binding to the receptor increases agonist affinity. We identified a camelid antibody fragment that exhibits G protein-like behavior towards the β2AR. Tylopoda (camels, dromedaries and llamas) have developed a unique class of functional antibody molecules that are devoid of light chains15. A nanobody (Nb) is the recombinant minimal-sized intact antigen-binding domain of such a camelid heavy chain antibody and is approximately 25% the size of a conventional Fab fragment. To generate receptor specific nanobodies, a llama was immunized with purified agonist bound β2AR reconstituted at high density into phospholipid vesicles. A library of single chain nanobody clones was generated and screened against agonist bound receptor. We identified seven clones that recognized agonist bound β2AR. Of these, Nb80, was chosen because it exhibited G-protein-like properties upon binding to both wild type β2AR and β2AR-T4L, the β2AR-T4 lysozyme fusion protein used to obtain the high-resolution inactive state crystal structure 7,9.

We compared the effect of Nb80 with Gs on β2AR structure and agonist binding affinity. β2AR was labeled at the cytoplasmic end of TM6 at C265 with monobromobimane and reconstituted into HDL particles. TM6 moves relative to TM3 and TM5 upon agonist activation (Fig. 1A), and we have previously shown that the environment around bimane covalently linked to C265 changes with both agonist binding and G protein coupling, resulting in a decrease in bimane intensity and a red shift in λmax 14. As shown in Fig. 1B, the catecholamine agonist isoproterenol and Gs both stabilize an active-like conformation, but the effect of Gs is greater in the presence of isoproterenol, consistent with the cooperative interactions of agonist and Gs on β2AR structure. Nb80 alone has an effect on bimane fluorescence and λmax of unliganded β2AR that is similar to that of Gs (Fig. 1C). This effect was not observed in β2AR bound to the inverse agonist ICI-118,551. The effect of Nb80 was increased in the presence of 10 μM isoproterenol. These results show that Nb80 does not recognize the inactive conformation of the β2AR, but binds efficiently to agonist occupied β2AR and produces a change in bimane fluorescence that is indistinguishable from that observed in the presence of Gs and isoproterenol.

Figure 1
Effect of Nb80 on β2AR structure and function

Figure 1D and E shows the effect of Gs and Nb80 on agonist affinity for β2AR. β2AR was reconstituted into HDL particles and agonist competition binding experiments were performed in the absence or presence of Nb80 and Gs. In the absence of either protein, isoproterenol has an inhibition constant (Ki) of 107 nM. In the presence of Gs two affinity states are observed, because not all of the β2AR is coupled to Gs. In the Gs coupled state the affinity of isoproterenol increases by 100-fold (Ki = 1.07 nM ) (Fig 1D and Table S1). Similarly, in the presence of Nb80 the affinity of isoproterenol increases by 95-fold (Ki = 1.13 nM) (Fig. 1E and Table S1). In contrast, Nb80 had little effect on β2AR binding to the inverse agonist ICI-118,551 (Supplementary Figure 1 and Table S1). These binding data suggest that Nb80 stabilizes a conformation in WT β2AR that is very similar to that stabilized by Gs, such that the energetic coupling of agonist and Gs binding is faithfully mimicked by Nb80.

The high-resolution structure of the inactive state of the β2AR was obtained with a β2AR-T4L fusion protein. We previously showed that β2AR-T4L has a higher affinity for isoproterenol than WT β2AR7. Nevertheless, in the presence of Nb80 the affinity increased by 60-fold, resulting in an affinity (Ki = 0.56 nM) comparable to that of WT β2AR bound to Nb80 (Fig 1F and Table S1). While we cannot study G protein coupling in β2AR-T4L due to steric hindrance by T4L, the results show that T4L does not prevent binding of Nb80, and the nearly identical Ki values for agonist binding to wild-type β2AR and β2AR-T4L in the presence of Nb80 suggest that Nb80 stabilizes a similar conformation in these two proteins. The most likely explanation for the ability of Nb80 to bind to β2AR-T4L while Gs does not is the difference in size of these two proteins. Nb80 is approximately 14 kDa while the Gs heterotrimer is approximately 90 kDa.

High affinity β2AR agonist

To further stabilize the active state of the β2AR, we screened over 50 commercial and proprietary β2AR ligands. Of these, BI-167107 (Boehringer Ingelheim) had the most favorable efficacy, affinity and off-rate profile. BI-167107 is a full agonist that binds to the β2AR with a dissociation constant Kd of 84 pM (Supplementary Figure 2A and B). As shown in Supplementary Fig 2C and D, BI-167107 induces a larger change in the fluorescence intensity and λmax of bimane bound to C265 than does the agonist isoproterenol. Moreover, the rate of dissociation of BI-167107 was extremely slow. Displacement of BI-167107 with an excess of the neutral antagonist alprenolol required 150 hours to complete as compared with 5 sec for isoproterenol.

Crystallization of β2AR-T4L-Nb80 complex

The β2AR was originally crystallized bound to the inverse agonist carazolol using two different approaches. The first crystals were obtained from β2AR bound to a Fab fragment that recognized an epitope composed of the amino and carboxyl terminal ends of the third intracellular loop connecting TMs 5 and 6 8. In the second approach, the third intracellular loop was replaced by T4 lysozyme (β2AR-T4L) 7. Efforts to crystallize β2AR-Fab complex and β2AR-T4L bound to BI-167107 and other agonists failed to produce crystals of sufficient quality for structure determination. We therefore attempted to crystallize BI-167107 bound to β2AR and β2AR-T4L in complex with Nb80. While crystals of both complexes were obtained in lipid bicelles and lipidic cubic phase (LCP), high-resolution diffraction was only obtained from crystals of β2AR-T4L-Nb80 grown in LCP. These crystals grew at pH 8.0 in 39–44% PEG400, 100 mM Tris, 4 % DMSO, and 1% 1,2,3-heptanetriol.

A merged data set at 3.5 Å was obtained from 23 crystals (Supplementary Table S2). The structure was solved by molecular replacement using the structure of the carazolol-bound β2AR and a nanobody as search models. Supplementary Figure 3A shows the packing of the β2AR-T4L-Nb80 complex in the crystal lattice. The receptor has interactions with lattice neighbors in several directions, and is relatively well ordered (Supplementary Figure 3A), with readily interpretable electron density for most of the polypeptide. Nb80 binds to the cytoplasmic end of the β2AR, with the third complementarity determining region (CDR) loop projecting into the core of the receptor (Figure 2A, and Supplementary Figure 4).

Figure 2
Comparison of the agonist-Nb80 stabilized crystal structures of the β2AR with inverse agonist bound β2AR and opsin

Agonist-stabilized changes in the β2AR

Figure 2B–D compares the inactive β2AR structure (from the carazolol boundβ2AR-T4L structure) with the agonist bound β2AR component of the β2AR-T4L-Nb80 complex. The largest differences are found at the cytoplasmic face of the receptor, with outward displacement of TM5 and TM6 and an inward movement of TM7 and TM3 in the β2AR-T4L-Nb80 complex relative to the inactive structure. There are relatively small changes in the extracellular surface (Fig. 2C). The second intracellular loop (ICL2) between TM3 and TM4 adopts a two-turn alpha helix (Fig. 2D), similar to that observed in the turkey β1AR structure 11. The absence of this helix in the inactive β2AR structure may reflect crystal lattice contacts involving ICL2.

Figure 2A and Supplementary Figure 4A–C show details of interaction of Nb80 with the cytoplasmic side of the β2AR. An eight amino acid sequence of CDR 3 penetrates into a hydrophobic pocket formed by amino acids from TM segments 3, 5, 6 and 7. A four amino acid sequence of CDR1 provides additional stabilizing interactions with cytoplasmic ends of TM segments 5 and 6. CDR3 occupies a position similar to the carboxyl terminal peptide of transducin in opsin 2 (Supplementary Fig 4C,D). The majority of interactions between Nb80 and the β2AR are mediated by hydrophobic contacts.

When comparing the agonist- and inverse agonist-bound structures, the largest change is observed in TM6, with an 11.4Å movement of the helix at Glu2686.30 (part of the ionic lock) (superscripts in this form indicate Ballesteros–Weinstein numbering for conserved GPCR residues16) (Fig. 2D). This large change is effected by a small clockwise rotation of TM6 in the turn preceding the conserved Pro2886.50, enabled by the interrupted backbone hydrogen bonding at the proline and repacking of Phe2826.44 (see below), which swings the helix outward.

The changes in agonist bound β2AR-T4L-Nb80 relative to the inactive carazolol-bound β2AR-T4L are remarkably similar to those observed between rhodopsin and opsin 2,3 (Fig. 2E). The salt bridge in the ionic lock between highly conserved Arg1313.50 and Asp/Glu1303.49 is broken. In opsin, Arg1353.50 interacts with Tyr2235.58 in TM5 and a backbone carbonyl of the transducin peptide. Arg1313.50 of β2AR likewise interacts with a backbone carbonyl of CDR3 of Nb80. However, Nb80 precludes an interaction between Arg1313.50 and Tyr2195.58, even though the tyrosine occupies a similar position in opsin and agonist bound β2AR-T4L-Nb80. As in opsin, Tyr3267.53 of the highly conserved NPxxY sequence moves into the space occupied by TM6 in the inactive state. In carazolol-bound β2AR-T4L we observed a network of hydrogen bonding interactions involving highly conserved amino acids in TMs 1, 2, 6 and 7 and several water molecules 7. While the resolution of the β2AR-T4L-Nb80 structure is inadequate to detect waters, it is clear that the structural changes we observe would substantially alter this network.

In contrast to the relatively large changes observed in the cytoplasmic domains of β2AR-T4L-Nb80, the changes in the agonist-binding pocket are fairly subtle. Figure 3 shows a comparison of the binding pockets of the inverse agonist and agonist bound structures. An omit map of the ligand-binding pocket is provided in Supplementary Figure 5. Many of the interactions between the agonist BI-167107 and the β2AR are similar to those observed with the inverse agonist carazolol. The alkylamine and the β-OH of both ligands form polar interactions with Asp1133.32 in TM3, and with Asn3127.39 and Tyr3167.43 in TM7. The agonist has a longer alkyl substituent on the amine, which ends with a phenyl ring that lies in a hydrophobic pocket formed by Trp1093.28, Phe1935.32 and Ile3097.36.

Figure 3
Ligand binding pocket of BI-167107 and carazolol bound β2AR structures

The greatest difference between inactive and active structures in the ligand-binding site is an inward bulge of TM5 centered around Ser2075.46, whose Cα position shifts by 2.1 Å (Fig. 4A). In addition, there are smaller inward movements of TM6 and TM7. The basal activity displayed by the β2AR suggests that the protein structure surrounding the binding pocket is relatively dynamic in the absence of ligand, such that it samples active and inactive conformations. The presence of Pro2115.50 in the following turn, which cannot form a hydrogen bond with the backbone at Ser2075.46, likely lowers the barrier to the transition between the conformations observed in the presence of carazolol and BI-167107. There are extensive interactions between the carbonyl oxygen, amine and hydroxyl groups on the heterocycle of BI-167107 and Ser2035.42 and 2075.46 in TM5, as well as Asn2936.55 in TM6 and Tyr3087.35 in TM7. In contrast, there is only one polar interaction between the nitrogen in the heterocycle of carazolol and Ser2035.42. Interactions of Ser2035.42, Ser2045.43 and Ser2075.46 with catecholamine hydroxyls have been proposed based on mutagenesis studies showing that these serines are important for agonist binding and activation 17,18. While Ser2045.43 does not interact directly with the ligand, it forms a hydrogen bond with Asn2936.55 on TM6, which is in turn linked to Tyr3087.35 of ECL3 (Fig. 3A). This tyrosine packs against Phe1935.32 of ECL2, and both residues move to close off the ligand-binding site from the extracellular space.

Figure 4
Rearrangement of transmembrane segment packing interactions upon agonist binding

Asn2936.55 contributes to enantiomeric selectivity for catecholamine agonists 19. The β-OH of BI-167107 does not interact with Asn2936.55, but forms hydrogen bonds with Asp1133.32 and Asn3127.39, similar to what is observed for carazolol in the inactive structure. The chirality of the β-OH influences the spatial position of the aromatic ring system in β2AR ligands, so the effect of Asn2936.55 on β-OH enantiomeric selectivity may arise from its direct interaction with the aromatic ring system of the ligand, as well as its positioning of Ser2045.43 and Tyr3087.35, which also interact with this portion of the ligand. However, BI-167107 is not a catecholamine, and it is possible that the β-OH of catecholamine agonists, such as epinephrine and norepinephrine, has a direct interaction with Asn2936.55, since mutation of Asn2936.55 has a stronger influence on the preference for the chirality of the β-OH of catecholamine agonists, compared with non-catechol agonists and antagonists19.

Trp6.48 is highly conserved in Family A GPCRs, and it has been proposed that its rotameric state plays a role in GPCR activation (rotamer toggle switch) 20. We observe no change in the side chain rotamer of Trp2866.48 in TM6 (Fig. 4A), which lies near the base of the ligand-binding pocket, although its position shifts slightly in concert with rearrangements of nearby residues Ile1213.40 and Phe2826.44. While there is spectroscopic evidence for changes in the environment of Trp6.48 upon activation of rhodopsin 21, a rotamer change is not observed in the crystal structures of rhodopsin and low-pH opsin. Moreover, recent mutagenesis experiments on the serotonin 5HT4 receptor demonstrate that Trp6.48 is not required for activation of this receptor by serotonin 22. These observations suggest that while changes in hydrophobic packing alter the conformation of the receptor in this region, changes in the Trp6.48 rotamer do not occur as part of the activation mechanism.

It is interesting to speculate how the small changes around the agonist-binding pocket are coupled to much larger structural changes in the cytoplasmic regions of TMs 5, 6 and 7 that facilitate binding of Nb80 and Gs. A potential conformational link is shown in Figure 4. Agonist interactions with Ser 2035.42 and 2075.46 stabilize a receptor conformation that includes a 2.1 Å inward movement of TM5 at position 2075.46 and 1.4 Å inward movement of the conserved Pro2115.50 relative to the inactive, carazolol-bound structure. In the inactive state, the relative positions of TM5, TM3, TM6 and TM7 are stabilized by interactions between Pro2115.50, Ile1213.40, Phe2826.44 and Asn3187.45. The position of Pro2115.50 observed in the agonist structure is incompatible with this network of interactions, and Ile1213.40 and Phe2826.44 are repositioned, with a rotation of TM6 around Phe2826.44 leading to an outward movement of the cytoplasmic end of TM6.

Although some of the structural changes observed in the cytoplasmic ends of transmembrane domains of the β2AR-T4L-Nb80 complex arise from specific interactions with Nb80, the fact that Nb80 and Gs induce or stabilize similar structural changes in the β2AR, as determined by fluorescence spectroscopy and by agonist binding affinity, suggests that Nb80 and Gs recognize similar agonist stabilized conformations. The observation that the transmembrane domains of rhodopsin and the β2AR undergo similar structural changes upon activation provides further support that the agonist-bound β2AR-T4L-Nb80 represents an active conformation and is consistent with a conserved mechanism of G protein activation.

However, the mechanism by which agonists induce or stabilize these conformational changes likely differs for different ligands and for different GPCRs. The conformational equilibria of rhodopsin and β2AR differ, as shown by the fact that rhodopsin appears to adopt a fully active conformation in the absence of a G protein23 whereas β2AR cannot 14. Thus, the energetics of activation and conformational sampling can differ among different GPCRs, which likely gives rise to the variety of ligand efficacies displayed by these receptors. An agonist need only disrupt one key intramolecular interaction needed to stabilize the inactive state, as constitutive receptor activity can result from single mutations of amino acids from different regions of GPCRs 24. Thus, disruption of these stabilizing interactions either by agonists or mutations lowers the energy barrier separating inactive and active states and increases the probability that a receptor can interact with a G protein.

METHODS SUMMARY

Crystallization

Preparation of β2AR-T4L and Nb80 are described in Supplementary Methods. BI-167107 bound β2AR-T4L and Nb80 preincubated in 1:1.2 molar ratio were mixed in monoolein containing 10% cholesterol in 1:1.5 protein to lipid ratio (w/w). Initial crystallization leads were identified and optimized in 24-well glass sandwich plates using 50 nL protein:lipid drops overlaid with 0.8 μl precipitant solution in each well and sealed with a glass cover slip. Crystals for data collection were grown at 20° C in hanging-drop format using 0.8 μl reservoir solution (36 to 44% PEG 400, 100 mM Tris pH 8.0, 4 % DMSO, 1 % 1,2,3-heptanetriol) diluted 2 to 4-fold in water. Crystals grew to full size, typically 40 x 5 x 5 μm3, within 7 to 10 days. Crystals were flash frozen and stored in liquid nitrogen with reservoir solution as cryoprotectant. Diffraction data collection and processing, and structure solution and refinement are described in Supplementary Methods.

METHODS (in supplemental information)

Preparation of β2AR-T4L and nanobody-80 for crystallography

β2AR-T4L was expressed in Sf-9 insect cell cultures infected with β2AR-T4L baculovirus, and solubilized according to previously described methods25. Functional protein was obtained by M1 FLAG affinity chromatography (Sigma) prior to and following alprenolol-Sepharose chromatography25. In the second M1 chromatography step, receptor-bound alprenolol was exchanged for high affinity agonist BI-167107 and dodecylmaltoside was exchanged for the MNG-3 amphiphile (11,11-Bis-β-D-maltopyranosidylmethyl-heneicosane, Supplementary Figure 6, obtained from Chae and Gellman, University of Wisconsin, Madison) for increased receptor stability. The agonist-bound and detergent-exchanged β2AR-T4L was eluted in 10 mM HEPES pH 7.5, 100 mM NaCl, 0.02% MNG-3, and 10 μM BI-167107 followed by removal of N-linked glycosylation by treatment with PNGaseF (NEB). The protein was concentrated to ~50 mg/ml with a 100 kDa molecular weight cut off Vivaspin concentrator (Vivascience).

Nanobody-80 (Nb80) bearing a C-terminal His6 tag was expressed in the periplasm of E. coli strain WK6 following induction with IPTG. Cultures of 0.6 L were grown to OD600 = 0.7 at 37°C in TB media containing 0.1% glucose, 2 mM MgCl2, and 50 μg/ml ampicillin. Induced cultures were grown overnight at 28°C. Cells were harvested by centrifugation and lysed in ice-cold buffer (50 mM Tris pH 8.0, 12.5 mM EDTA, and 0.125 M sucrose), then centrifuged to remove cell debris. Nb80 was purified by nickel affinity chromatography, dialysed against buffer (10 mM HEPES pH 7.5, 100 mM NaCl), and spin concentrated to ~120 mg/ml.

Crystallization

BI-167107 bound β2AR-T4L and Nb80 were mixed in 1:1.2 molar ratio, incubated 2 hours at RT before mixing with liquefied monoolein (M7765, Sigma) containing 10% cholesterol (C8667, Sigma) in 1:1.5 protein to lipid ratio (w/w) using the twin-syringe mixing method developed by Martin Caffrey26. Initial crystallization leads were identified using in-house screens and optimized in 24-well glass sandwich plates using 50 nL protein:lipid drops manually delivered and overlaid with 0.8 μl precipitant solution in each well and sealed with a glass cover slip. Crystals for data collection were grown at 20°C by hanging drop vapor diffusion using 0.8 μl reservoir solution (36 to 44% PEG 400, 100 mM Tris pH 8.0, 4 % DMSO, 1 % 1,2,3-heptanetriol) diluted 2 to 4-fold in Milli-Q water. Crystals grew to full size within 7 to 10 days. Crystals were flash frozen and stored in liquid nitrogen with reservoir solution as cryoprotectant.

Microcrystallography data collection and processing

Diffraction data were measured at beamline 23-ID of the Advanced Photon Source, using a 10 μm diameter beam. Low dose 1.0° rotation images were used to locate and center crystals for data collection. Data were measured in 1.0° frames with exposure times typically 5–10 sec with a 5x attenuated beam. Only 5–10° of data could be measured before significant radiation damage occurred. Data were integrated and scaled with the HKL2000 package 27.

Structure solution and refinement

Molecular replacement phases were obtained with the program Phaser 28. The search models were 1) the high-resolution carazolol-bound β2AR structure, PDB id 2RH1, but with T4L and all water, ligand and lipid molecules removed) and a nanobody (PDB id 3DWT, water molecules removed) as search models. The rotation and translation function Z scores were 8.7 and 9.0 after placing the β2AR model, and the nanobody model placed subsequently had rotation and translation function Z scores of 3.5 and 11.5. The model was refined in Phenix 29 and Buster30, using a group B factor model with one B for main chain and one B for side chain atoms. Refinement statistics are given in Table S2. Despite the strong anisotropy (Table S2), the electron density was clear for the placement of side chains.

Ligand binding on receptor reconstituted in HDL particles

The effect of Nb80 and Gs on the receptors affinity for agonists was compared in competition binding experiments. The β2AR and β2AR-T4L (both truncated at position 365) purified as previously described7,8 were reconstituted in high-density lipoprotein (HDL) particles followed by reconstitution of Gs into HDL particles containing β2AR according to previously published methods 31. 0.6 nM [3H]-dihydroalprenolol ([3H]-DHA) was used as radioligand and agonist (−)-isoproterenol (ISO) or inverse agonist ICI-118,551 (ICI) as competitor. Nb80 was used at 1 μM. GTPγS was used at 10 μM. TBS (50 mM Tris pH 7.4, 150 mM NaCl) containing 0.1% BSA was used as binding buffer. Bound 3H-DHA was separated from unbound on a Brandel harvester by passing over a Whatman GF/B filter (presoaked in TBS with 0.3% polyethylenimine) and washed in cold TBS. Radioligand binding was measured in a Beckman LS6000 scintillation counter. Ligand binding affinity (Kd) of DHA was determined from saturation binding curves using GraphPad Prism software. Normalized ISO competition binding data were fit to a two-site competition binding model by using GraphPad Prism. Binding affinities of ISO (Ki values, tabulated in Table S1) were determined from IC50 values using the equation equation M1.

cAMP Assay

To determine the functional potency of BI-167107, changes in intracellular cAMP levels were determined with CHO-hβ2AR cells in suspension (15,000 cells/well) by using Alphascreen technology (PerkinElmer Life and Analytical Sciences) and a 384-well plate format (Optiplate; PerkinElmer Life and Analytical Sciences), according to the manufacturer’s protocol. In brief, cells were stimulated with the respective agonists at different concentrations in Hanks’ buffered saline solution supplemented with 5 mM HEPES, 0.1% bovine serum albumin, and 500 mM 3-isobutyl-1-methylxanthine for 30 min at room temperature. Cells were lysed by using Alphascreen reagents. After 2 h, plates were read on an Envision plate reader (PerkinElmer Life and Analytical Sciences). The concentration of cAMP in the samples was calculated from a standard curve.

Bimane fluorescence spectroscopy on β2AR reconstituted in HDL particles

To compare the effects on receptor conformation of Gs and Nb80 binding the purified β2AR was labeled with the environmentally sensitive fluorescent probe monobromo-bimane (Invitrogen) at cysteine 265 located in the cytoplasmic end of TM6, and reconstituted into HDL particles (mBB-β2AR/HDL). Prior to obtaining fluorescence emission spectra, 10 nM mBB-β2AR/HDL was incubated 30 min at RT in buffer (20 mM HEPES pH 7.5, 100 mM NaCl) in the absence or presence of 10 μM ISO, 1 μM ICI, 300 nM Gs heterotrimer, or 300 nM Nb80, or in combinations of ISO with Gs, ISO with Nb80, and ICI with Nb80. Fluorescence spectroscopy was performed on a Spex FluoroMax-3 spectrofluorometer (Jobin Yvon Inc.) with photon-counting mode, using an excitation and emission bandpass of 5 nm. Excitation was set at 370 nm and emission was collected from 415 to 535 nm in 1 nm increments with 0.3 sec/nm integration time. Fluorescence intensity was corrected for background fluorescence from buffer and ligands. The curves shown in Figure 1B and 1C are each the average of triplicate experiments.

High affinity β2AR agonist screening by bimane fluorescence spectroscopy

To obtain high affinity agonist candidates with slow dissociation rates for crystallography, a screening process of commercially available drugs and compound libraries from medicinal and biotech industry was initiated. Screening was conducted in several rounds on more than 50 compounds. 10 μM of each compound incubated with 100 nM purified mBB-β2AR in DDM buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 0.1% dodecylmaltoside (DDM)) for 30 min at RT prior to emission scanning, using same equipment and settings as described in the section above. Compounds inducing the largest red shift in λmax and decrease in bimane fluorescence emission were identified. Closely related structural analogs were subsequently screened using same criteria for selection. Several lead candidate compounds were then subjected to dissociation experiments to identify the agonist with the slowest rate of dissociation. In these experiments, 100 nM mBB-β2AR was incubated with 1 μM lead compound in DDM buffer for 2 hours at RT before obtaining the emission scan at t=0 (example in figure 2D, green spectra). An excess amount (200 μM) of the neutral antagonist alprenolol (ALP) was added to identical samples followed by measurement of bimane emission at various time points in a period up to 7 days or until complete dissociation of agonist.

Supplementary Material

Acknowledgments

We acknowledge support from National Institutes of Health Grants NS028471 and GM083118, and GM56169 (W.I.W.), a grant from Boerhinger Ingelheim (B.K.K.), the Mathers Foundation (B.K.K and W.I.W), the Lundbeck Foundation (Junior Group Leader Fellowship, S.G.F.R.), the Fund for Scientific Research of Flanders (FWO-Vlaanderen) and the Institute for the encouragement of Scientific Research and Innovation of Brussels (ISRIB) (E.P. and J.S.).

Footnotes

Supplementary Information is linked to the online version of the paper at www.nature.com/nature

Author Contributions S.G.F.R. screened and characterized high affinity agonists, identified and determined dissociation rate of BI-167107, screened, identified and characterized MNG-3, performed selection and characterization of nanobodies, purified and crystallized the receptor with Nb80 in LCP, optimized crystallization conditions, grew crystals for data collection, reconstituted receptor in HDL particles and determined the effect of Nb80 and Gs on receptor conformation and ligand binding affinities, assisted with data collection and preparing the manuscript. H.J.C. managed data processing, solved and refined the structure, and assisted with preparing the manuscript. J.J.F. expressed, purified, selected and characterized nanobodies, purified and crystallized receptor with nanobodies in bicelles, assisted with growing crystals in LCP, and assisted with data collection. E.P. performed immunization, cloned and expressed nanobodies, and performed the initial selections. J.S. supervised nanobody production. P.S.K. and S.H.G. provided MNG-3 detergent for stabilization of purified β2AR. B.D. and R.K.S. provided ApoA1 and Gs protein, and reconstituted β2AR in HDL particles with Gs. D.R. characterized the usefulness of MNG-3 for crystallization in LCP and assisted with manuscript preparation. F.S.T. expressed β2AR in insect cells and with T.S.K performed the initial stage of β2AR purification. A.P., A.S. assisted in selection of the high-affinity agonoist BI-167,107. I.K. synthesized BI-167,107. P.C. characterized the functional properties of BI-167,107 in CHO cells. W.I.W. oversaw data processing, structure determination and refinement, and assisted with manuscript preparation. B.K.K. was responsible for the overall project strategy and management, prepared β2AR in lipid vesicles for immunization, harvested and collected data on crystals, wrote the manuscript.

Author Information Reprints and permissions information is available at www.nature.com/reprints). Coordinates and structure factors forβ2AR-Nb80 are deposited in the Protein Data Bank (accession code 3P0G).

References

1. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356–363. [PubMed]
2. Scheerer P, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature. 2008;455:497–502. [PubMed]
3. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature. 2008;454:183–U133. [PubMed]
4. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol. 2004;343:1409–1438. [PubMed]
5. Palczewski K, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000;289:739–745. [PubMed]
6. Vogel R, Siebert F. Conformations of the active and inactive states of opsin. Journal of Biological Chemistry. 2001;276:38487–38493. [PubMed]
7. Rosenbaum DM, et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science. 2007;318:1266–1273. [PubMed]
8. Rasmussen SG, et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature. 2007;450:383–387. [PubMed]
9. Cherezov V, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science. 2007;318:1258–1265. [PMC free article] [PubMed]
10. Hanson MA, et al. A specific cholesterol binding site is established by the 2.8 angstrom structure of the human beta(2)-adrenergic receptor. Structure. 2008;16:897–905. [PMC free article] [PubMed]
11. Warne T, et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature. 2008;454:486–491. [PMC free article] [PubMed]
12. Jaakola VP, et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist. Science. 2008 [PMC free article] [PubMed]
13. Ghanouni P, et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem. 2001;276:24433–24436. [PubMed]
14. Yao XJ, et al. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci U S A. 2009;106:9501–9506. [PubMed]
15. Hamers-Casterman C, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–448. [PubMed]
16. Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein coupled receptors. Meth Neurosci. 1995;25:366–428.
17. Strader CD, et al. Identification of residues required for ligand binding to the β-adrenergic receptor. Proc Natl Acad Sci U S A. 1987;84:4384–4388. [PubMed]
18. Liapakis G, et al. The forgotten serine. A critical role for Ser-2035.42 in ligans binding to and activation of the beta 2-adrenergic receptor. J Biol Chem. 2000;275:37779–37788. [PubMed]
19. Wieland K, Zuurmond HM, Krasel C, Ijzerman AP, Lohse MJ. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc Natl Acad Sci U S A. 1996;93:9276–9281. [PubMed]
20. Shi L, et al. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem. 2002;277:40989–40996. [PubMed]
21. Ahuja S, Smith SO. Multiple switches in G protein-coupled receptor activation. Trends Pharmacol Sci. 2009;30:494–502. [PubMed]
22. Pellissier LP, et al. Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors. Mol Pharmacol. 2009;75:982–990. [PubMed]
23. Altenbach C, Kusnetzow AK, Ernst OP, Hofmann KP, Hubbell WL. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. Proc Natl Acad Sci U S A. 2008;105:7439–7444. [PubMed]
24. Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, Clauser E. Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab. 2002;13:336–343. [PubMed]
25. Kobilka BK. Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal Biochem. 1995;231:269–271. [PubMed]
26. Caffrey M, Cherezov V. Crystallizing membrane proteins using lipidic mesophases. Nat Protoc. 2009;4:706–731. [PMC free article] [PubMed]
27. Otwinowski Z, Minor W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–326.
28. McCoy AJ, et al. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658–674. [PubMed]
29. Afonine PV, Grosse-Kunstleve RW, Adams PD. A robust bulk-solvent correction and anisotropic scaling procedure. Acta Crystallogr D Biol Crystallogr. 2005;61:850–855. [PMC free article] [PubMed]
30. Blanc E, et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr D Biol Crystallogr. 2004;60:2210–2221. [PubMed]
31. Whorton MR, et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci U S A. 2007;104:7682–7687. [PubMed]
32. Zhang XJ, Wozniak JA, Matthews BW. Protein flexibility and adaptability seen in 25 crystal forms of T4 lysozyme. J Mol Biol. 1995;250:527–552. [PubMed]